The U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib in May 2020 for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castrate resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and taxane.